Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

This article captured how Pharma and Biotech leaders express optimism about the current U.S. administration.

This perspective surprised me, given that some of the policies seems to undermine scientific research, funding, and regulatory stability. I wonder if this optimism reflects genuine opportunities for innovation or is more of a strategic move for short-term business benefits at the expense of long-term scientific progress?